Alliance Pharma PLC AGM Statement (1643G)
May 25 2017 - 2:00AM
UK Regulatory
TIDMAPH
RNS Number : 1643G
Alliance Pharma PLC
25 May 2017
For immediate release 25 May 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
AGM Statement
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical
company, will hold its Annual General Meeting ("AGM") in London
later this morning. At the meeting, the Company's Chairman, Andrew
Smith, will make the following statement:
"The year is proceeding well for the Company as we continue to
develop our pan-European business.
"Trading in the current financial year is good and in line with
the Board's expectations. Our key international growth brands,
Kelo-Cote(TM), for scar reduction, and MacuShield(TM), a
nutritional supplement product for age-related macular degeneration
(AMD), continue to deliver a strong performance.
"We continue to expect that the UK registration approval for
Diclectin, for the treatment for nausea and vomiting of pregnancy,
will be granted in Q3 2017, which will enable us to begin
commercial sales around the end of 2017 with sales in European
territories following approximately 12 months later.
"Cash flow in the business remains strong and we are on target
to reduce our adjusted net debt/EBITDA ratio to around 2x by the
end of the year.
"We look forward to the year ahead with much confidence."
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMOKQDQABKDQPB
(END) Dow Jones Newswires
May 25, 2017 02:00 ET (06:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024